Susan Manzi

Active 1984–2025

Also published as
SUSAN MANZI
90
Papers
19,356
Citations
61
h-index
87
i10-index

Citations

Citations per year for Susan Manzi1983: 1 citations1984: 2 citations1993: 1 citations1996: 1 citations1997: 4 citations1998: 5 citations1999: 9 citations2000: 22 citations2001: 17 citations2002: 31 citations2003: 33 citations2004: 34 citations2005: 61 citations2006: 72 citations2007: 62 citations2008: 92 citations2009: 153 citations2010: 134 citations2011: 162 citations2012: 147 citations2013: 155 citations2014: 122 citations2015: 139 citations2016: 162 citations2017: 145 citations2018: 152 citations2019: 588 citations2020: 574 citations2021: 596 citations2022: 482 citations2023: 336 citations2024: 626 citations2025: 265 citations2026: 2 citations1985–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,801 citing papers, 22.9% of this breakdownUnited Kingdom: 597 citing papers, 7.6% of this breakdownChina: 523 citing papers, 6.6% of this breakdownItaly: 397 citing papers, 5% of this breakdownCanada: 333 citing papers, 4.2% of this breakdownSweden: 323 citing papers, 4.1% of this breakdownGermany: 301 citing papers, 3.8% of this breakdownFrance: 295 citing papers, 3.8% of this breakdownSpain: 291 citing papers, 3.7% of this breakdownJapan: 225 citing papers, 2.9% of this breakdownNetherlands: 214 citing papers, 2.7% of this breakdownAustralia: 187 citing papers, 2.4% of this breakdown
0%22.9%Other 30.3%

Fields

  • Medicine79.8%
  • Immunology and Microbiology10.3%
  • Biochemistry, Genetics and Molecular Biology7.9%
  • Neuroscience0.6%
  • Health Professions0.2%
  • Psychology0.2%
  • Other1%

Topics

  • Systemic Lupus Erythematosus Research22.3%
  • Rheumatoid Arthritis Research and Therapies6.1%
  • T-cell and B-cell Immunology5.3%
  • Systemic Sclerosis and Related Diseases3.6%
  • Monoclonal and Polyclonal Antibodies Research3.5%
  • Atherosclerosis and Cardiovascular Diseases3.3%
  • Other55.9%

Coauthors

All papers

Open in search
  1. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mary Anne Dooley, Ronald van Vollenhoven, Ellen M. Ginzler, Thomas Stoll, Christine Peschken, Joseph L. Jorizzo, Jeffrey P. Callen, S. Sam Lim, Barri J. Fessler, Murat İnanç, Diane L. Kamen, Anisur Rahman, Kristján Steinsson, Andrew G. Franks, Lisa Sigler, Suhail Hameed, Hong Fang, Ngoc Minh Pham, Robin L. Brey, Michael H. Weisman, Gerald McGwin, Laurence S. Magder - Arthritis & Rheumatism 2012 cited by 5,295

  2. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , - The Lancet Rheumatology 2019 cited by 482

  3. The frequency and outcome of lupus nephritis: results from an international inception cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Asad Zoma, Manuel Ramos‐Casals, Guillermo Ruiz‐Irastorza, S. Sam Lim, Thomas Stoll, Murat İnanç, Kenneth Kalunian, Diane L. Kamen, Peter J. Maddison, Christine Peschken, Søren Jacobsen, Anca Askanase, Chris Theriault, Kara Thompson, Vernon T. Farewell - Lara D. Veeken 2015 cited by 632

  4. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

    Authors: , , , , , , , , , , , , , , - Arthritis & Rheumatology 2022 cited by 152

  5. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

    Authors: , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 142

  6. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Meggan Mackay, Manuel Ramos‐Casals, Ronald van Vollenhoven, Kenneth Kalunian, Guillermo Ruiz‐Irastorza, Sam Lim, Diane L. Kamen, Christine Peschken, Murat İnanç, Murray B. Urowitz - Annals of the Rheumatic Diseases 2014 cited by 566

  7. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2005 cited by 666

  8. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Guillermo Ruiz‐Irastorza, Sam Lim, Murat İnanç, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader - Annals of the Rheumatic Diseases 2023 cited by 81

  9. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Manuel Ramos‐Casals, Kristján Steinsson, Asad Zoma, Anca Askanase, Munther A. Khamashta, Ian N Bruce, Murat İnanç, Michał Abrahamowicz, Sasha Bernatsky - Annals of the Rheumatic Diseases 2021 cited by 98

  10. Association of Systemic Lupus Erythematosus with C8orf13–BLK and ITGAM–ITGAX

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2008 cited by 917

  11. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael F. Seldin, Lars Rönnblom, Lindsey A. Criswell, Ann-Christine Syvänen, Timothy W. Behrens, Robert Graham - Nature Genetics 2009 cited by 809

  12. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

    Authors: , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2012 cited by 407

  13. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Peschken, Diane L. Kamen, Anca Askanase, Bernardo A. Pons‐Estel, Graciela S. Alarcón - Annals of the Rheumatic Diseases 2022 cited by 56

  14. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Peschken, Diane L. Kamen, Anca Askanase, Vernon T. Farewell - Annals of the Rheumatic Diseases 2020 cited by 77

  15. A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

    Authors: , , , , , , , - Arthritis & Rheumatism 2003 cited by 617

  16. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Peschken, Bernardo A. Pons‐Estel, Anisur Rahman, Rosalind Ramsey‐Goldman, John A. Reynolds, Juanita Romero‐Díaz, Guillermo Ruiz‐Irastorza, Jorge Sánchez‐Guerrero, Elisabet Svenungsson, Murray B. Urowitz, Évelyne Vinet, Ronald van Vollenhoven, Alexandre E. Voskuyl, Daniel J. Wallace, Michelle Petri, Susan Manzi, Ann E. Clarke, Mike W.‐L. Cheung, Vernon T. Farewell, Graciela S. Alarcón - Lupus Science & Medicine 2021 cited by 91

  17. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus

    Authors: , , , , , , , , , , , , , , , - Nature Genetics 2008 cited by 463

  18. Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2014 cited by 150

  19. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Meggan Mackay, Guillermo Ruiz‐Irastorza, Manuel Ramos‐Casals, S. Sam Lim, Murat İnanç, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Chris Theriault, Vernon T. Farewell - Arthritis & Rheumatology 2018 cited by 101

  20. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Murat İnanç, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, N. Costedoat‐Chalumeau - Arthritis & Rheumatology 2023 cited by 41

  21. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials

    Authors: , , , , , , , - Lara D. Veeken 2022 cited by 40

  22. Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes

    Authors: , , , , , , , , , , , , , , , , , - PLoS Genetics 2011 cited by 205

  23. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Manuel Ramos‐Casals, Guillermo Ruiz‐Irastorza, S. Sam Lim, Kenneth Kalunian, Murat İnanç, Diane L. Kamen, Christine Peschken, Søren Jacobsen, Anca Askanase, Chris Theriault, Kara Thompson, Vernon T. Farewell - Arthritis & Rheumatology 2015 cited by 127

  24. Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus

    Authors: , , , , , , , , , , , , , , , , , , - PLoS Genetics 2008 cited by 218